Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone
Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use
Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone
Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use
Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook
Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4
Jim Birchenough Recent News
Uniqure Notches Bullish Initiation On Gene Therapy Prospects
Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades
Bellicum Rallies After FDA Lifts Clinical Hold
Akcea Therapeutics Downgraded By Wells Fargo After Huge Run
Wall Street Reacts To Celgene's Reported Interest In Juno
Arena Pharma Upgraded Ahead Of Clinical Data Release
Infinity Pharmaceuticals Notches Upgrade Ahead Of Cancer Conference Presentation
FDA Warning Letter Buckles Intercept Pharma Shares; Wells Fargo Downgrades
Analysts Weigh In On Gilead-Kite Pharma Deal
Clinical Hold For Regulus' RG101 Sparks A Downgrade At Wells Fargo
Legal Experts Weigh In On The Amgen/Regeneron Patent Case
Global Blood Therapeutics Shares Spiking On Analyst's Positive Outlook
Ziopharm Oncology Downgraded By BMO As 'Questions Persist'
BMO: Celgene Still A Buy On This 'Important Future Driver'
BMO Capital: Five Prime Therapeutics Still A Buy, Worth $31/Share Now
Regeneron Shares Fall Following BMO's Note Of Roche Preference
Ariad Shares Continue to Surge Amidst Buyout Rumors
UPDATE: BMO Capital Markets Upgrades Tesaro
Tesaro Shares Tumble After Disappointing Data Results
UPDATE: BMO Capital Markets Reiterates on Receptos Following Solid 3Q13 Operating Results
UPDATE: BMO Capital Markets Reiterates on Gilead Sciences Following Solid 3Q13 Results
UPDATE: BMO Capital Markets Downgrades Ariad Pharmaceuticals on AP26113 Disappointment, Tempered ICLUSIG Expectations
UPDATE: BMO Capital Markets Raises PT on Regulus Therapeutics Following 2Q13 Operating Results